🔎 Trials Near Me

Home › Multiple Myeloma › Montana

Pag-aaral pangklinika para sa Multiple Myeloma sa Montana

5 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Montana.

Mga Lungsod sa Montana

Opisyal na teksto ng pag-aaral (English)

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Benefis Sletten Cancer Institute, Great Falls
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06948084

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Saint Patrick Hospital - Community Hospital, Missoula
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04566328

Integrated Cancer Repository for Cancer Research

  • Bozeman Health Deaconess Hospital, Bozeman
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Saint Patrick Hospital - Community Hospital, Missoula
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  • GSK Investigational Site, Billings
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT06679101

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.